1. Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
- Author
-
James Artingstall, Alex Friedlaender, Alfredo Addeo, Judith Cave, Massimo Di Maio, Samuel Chan, Alessio Cortellini, Marcello Tiseo, Biagio Ricciuti, Francesco Facchinetti, Benjamin Besse, Joao V Alessi, Mark M Awad, David J Pinato, Giuseppe L Banna, Giuseppe Lamberti, Margarita Majem, Frank Aboubakar Nana, Charles Comins, Thomas Newsom-Davis, Victor R Vaz, Laura Mezquita, Davide Soldato, Filippo G Dall’Olio, Sethupathi Muthuramalingam, Aida Piedra, Elisa Andrini, Teresa Gorría, Delphine Hoton, Lacroix Valerie, Andrea Caglio, Hayley McKenzie, Joanne S Evans, Antonio D'Alessio, and Claudia A M Fulgenzi
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Introduction It has been recognized that increasing body mass index (BMI) is associated with improved outcome from immune checkpoint inhibitors (ICIs) in patients with various malignancies including non-small cell lung cancer (NSCLC). However, it is unclear whether baseline BMI may influence outcomes from first-line chemoimmunotherapy combinations.Methods In this international multicenter study, we evaluated the association between baseline BMI, progression-free survival (PFS) and overall survival (OS) in a cohort of patients with stage IV NSCLC consecutively treated with first-line chemoimmunotherapy combinations. BMI was categorized according to WHO criteria.Results Among the 853 included patients, 5.3% were underweight; 46.4% were of normal weight; 33.8% were overweight; and 14.5% were obese. Overweight and obese patients were more likely aged ≥70 years (p=0.00085), never smokers (p
- Published
- 2022
- Full Text
- View/download PDF